

AMENDMENTS TO THE SPECIFICATION:

Please insert the following heading on page 1, between lines 2 and 3:

--FIELD OF THE INVENTION--

Please insert the following heading on page 1, between lines 10 and 11:

--BACKGROUND OF THE INVENTION--

Please replace the paragraph on page 2, beginning on line 18, with the following re-written paragraph:

--SUMMARY OF THE INVENTION

~~However, in~~ In a quite surprising and unexpected way, the inventors have shown a therapeutic activity and, more specifically, a dermatological and cosmetic activity of these UCP proteins and/or these polypeptide or peptide fragments, particularly when these peptides and/or these peptide fragments are applied to the skin.--

Please insert the following heading on page 3, between lines 8 and 9:

--DETAILED DESCRIPTION OF THE INVENTION--

Please replace the paragraph on page 3, beginning on line 9, with the following re-written paragraph:

--Preferentially according to the invention, the peptide fragments are peptides of formula (I):

(I) (AA)_n - Pro - X₁ - X₂ - X₁ - X₃ - Lys - X₁ - Arg - X₄ - X₅ - (AA)_n (SEQ ID NO:10)

wherein:

X₁ = Leu, Thr, Val;

X₂ = Asp, Glu;

X₃ = Ala, Val;

X₄ = Leu, Phe, Tyr;

X₅ = Gln, Ile, Met;

and where (AA) is any particular amino acid or one of its derivatives, and n is a whole number ranging from 0 to 2.--

Please replace the paragraph on page 8, beginning on line 20, with the following re-written paragraph:

--In an advantageous way the composition according to the invention contains one or more peptides chosen among peptides corresponding to ~~sequences ID N° (1) to ID N° (9)~~ SEQ ID NO:1 to SEQ ID NO:9. According to a particularly advantageous embodiment of the invention, the composition contains the peptide of sequence Pro-Leu-Asp-Thr-Ala-Lys-Val-Arg-Leu-Gln (SEQ ID NO:1).

In a more general way, the composition, according to the invention, contains the active compound previously defined.--

Please replace the paragraph on page 12, beginning on line 29, with the following re-written paragraph:

--3T3-L1 cells, seeded in 8-well Lab-Teks, were treated with the peptide of ~~sequence ID N°(1)~~ SEQ ID NO:1, i.e. of sequence Pro-Leu-Asp-Thr-Ala-Lys-Val-Arg-Leu-Gln, representative of the peptide family according to the invention, placed in a 0.5% solution at 50 ppm. The active ingredient was added at various stages of culture:

- At the start of the incubation and until the end of adipocyte differentiation (72 hours of culture until 100% confluence, then for the 6 days of differentiation);
- 6 hours after incubation and until the end of cell differentiation (66 hours of culture until 100% confluence, then for the 6 days of differentiation);
- Once cells differentiated in the adipocytes, they were treated with the active ingredient for 6, 24, or 48 hours.--

Please replace the paragraph on page 15, beginning on line 13, with the following re-written paragraph:

--Differentiated 3T3-L1 cells were treated with a 0.5% solution at 50 ppm, containing the peptide of ~~sequence ID N°(1)~~ SEQ ID NO:1, representative of the peptide family according to

the invention, for periods of 1 h 30, 3 h, 5 h, 7 h and 24 h.--

Please replace the Example beginning on page 17, beginning with line 1 and the entire table, with the following re-written paragraph and table:

-- **Example 2** - Preparation of compositions.

1. Slimming Cream

<i>Commercial Names</i>	<i>INCI Names</i>	<i>% mass</i>
<i>PHASE A</i>		
Montanov 68 <u>MONTANOV 68®</u>	Cetearyl Alcohol (and) Cetearyl Glucoside	5.00
Squalane	Squalane	2.50
DUB IPP	Isopropyl Palmitate	3.50
Eutanol G <u>EUTANOL G®</u>	Octyldodecanol	1.50
Phenonip <u>PHENONIP®</u>	Phenoxyethanol (and) Methylparaben (and) Ethylparaben (and) Butylparaben (and) Propylparaben (and) Isobutylparaben	0.50
<i>PHASE B</i>		
Demineralized water	Aqua (Toilets)	qs
Glycerine	Glycerin	3.00
Butylene Glycol	Butylene glycol	3.00
<i>PHASE C</i>		
Simulgel EG <u>SIMULGELEG®</u>	Sodium Acrylate/Acryloyldimethyl	0.60

	Taurate Copolymer (and) Isohexadecane (and) Polysorbate 80	
PHASE D		
Peptide HN^o(1) <u>SEQ ID NO:1</u>		1.25 ppm
Perfume	Perfume (Fragrance)	qs
Colorant		qs

--

Please replace the Table beginning on page 18, line 7,
 with the following re-written Table:

--2. Firming - Slimming Spray

Commercial Names	INCI Names	% mass
PHASE A		
Emulgade SEV <u>EMULGADE SEV®</u>	Glyceryl Stearate (and) Ceteareth-20 (and) Ceteareth-12 (and) Cetearyl Alcohol	4.60
Emulgin B2 <u>EUMULGIN B2®</u>	Ceteareth-20	1.40
Cetiol OE <u>CETIOL OE®</u>	Dicaprylyl Ether	3.00
DUB B1215	C12-C15 Alkyl Benzoate	5.00
Phenonip <u>PHENONIP®</u>	Phenoxyethanol (and) Methylparaben (and) Ethylparaben (and) Butylparaben (and) Propylparaben (and) Isobutylparaben	0.50
DUB ININ	Isononyl Isononanoate	5.00
Phenonip <u>PHENONIP®</u>	Phenoxyethanol (and) Methylparaben (and) Ethylparaben (and) Butylparaben (and) Propylparaben (and) Isobutylparaben	0.50
PHASE B		
Demineralized water	Aqua (Toilets)	15.00

<i>Commercial Names</i>	<i>INCI Names</i>	<i>% mass</i>
Glycerine	Glycerin	3.00
PHASE C		
Demineralized water	Aqua (Toilets)	qs
PHASE D		
Peptide ID-N°(1) <u>SEQ ID NO:1</u>		1.50 ppm
Perfume	Perfume (Fragrance)	qs
Colorant		qs

--

Please replace the Table beginning on page 19, line 8,
 with the following re-written Table:

--3. Firming - Slimming - Anti-Cellulite Gel

<i>Commercial Names</i>	<i>INCI Names</i>	<i>% mass</i>
Carbopol Ultrez 10 (2%) CARBOPOL ULTREZ® 10 (2%)	Carbomer	25.00
Demineralized water	Aqua (Toilets)	qs
DUB DIOL	Methyl Propanediol	3.00
EDTA	Tetrasodium EDTA	0.10
Glydant Plus Liquid	DMDM Hydantoin (and) Iodopropynyl butylcarbamate	0.20
Peptide ID-N°(1) <u>SEQ ID NO:1</u>		1.25 ppm
TEA	Triethanolamine	0.50
Perfume	Perfume (Fragrance)	qs
Water-soluble colorant		qs

--